A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
← catalyst calendarNCT06873945 · readout in 578 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,330estimated
Sites
147
Countries
Canada, China, Czechia +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-01 | actual | When the study began enrolling |
| Primary completion | 2028-03-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-19 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: Ritlecitinib 100 mg — also filed as PF-06651600, Litfulo
- Drug: Ritlecitinib 50 mg — also filed as PF-06651600, Litfulo
- Drug: Placebo - 100 mg
- Drug: Placebo - 50 mg
Primary outcomes
what the primary-completion date above is the date OFPart 1: Percentage of participants with absolute Severity of Alopecia Tool (SALT) score less than or equal to 20
measured Week 24
Part 2: Percentage of participants with TEAEs, SAEs, and AEs leading to discontinuation
measured Baseline to Follow-up visit (Week 52)
Part 2: Percentage of participants with clinically significant laboratory abnormalities
measured Baseline to Follow-up visit (Week 52)
Publications
- PMID 41083802 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed